Search
Sunshine Biopharma Inc
SBFMAdd to Watchlist
2.110USD
-0.070-3.21%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.04MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.21%
5 Days
-3.21%
1 Month
-17.90%
6 Months
+64.84%
Year to Date
+71.54%
1 Year
+36.13%
Key Figures
2.150Open
2.200High
51.13KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
10.42%Turnover Ratio
2.180Prev. Close
2.100Low
69.39KTurnover
LossP/E Static
0.05P/B
0.00%Div Yield TTM
-21.15%ROA
2.43052wk High
1.36Volume Ratio
-5.13MNet Profit
490.59KShares
-1.2545EPS TTM
1.36Beta
-27.33%ROE
0.28152wk Low
4.59%Amplitude
26.01%Gross Margin
1.04MMarket Cap
-2.29Reward/Risk
6.62%Risk Rate
TradingKey Stock Score of Sunshine Biopharma Inc
Currency: USD Updated: 2026-07-02Key Insights
Sunshine Biopharma Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 60.00.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sunshine Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sunshine Biopharma Inc Highlights
StrengthsRisks
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.69% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.31M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 36.31M.
Undervalued
The company’s latest PE is -1.68, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 253.46K shares, decreasing 57.72% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.75.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
60.000
Target Price
+2652.29%
Upside Space
Sunshine Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sunshine Biopharma Inc Info
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Ticker SymbolSBFM
CompanySunshine Biopharma Inc
CEOSlilaty (Steve N)
Websitehttps://www.sunshinebiopharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Sunshine Biopharma Inc (SBFM)?
The current price of Sunshine Biopharma Inc (SBFM) is 2.11.
What is the symbol of Sunshine Biopharma Inc?
The ticker symbol of Sunshine Biopharma Inc is SBFM.
What is the 52-week high of Sunshine Biopharma Inc?
The 52-week high of Sunshine Biopharma Inc is 2.43.
What is the 52-week low of Sunshine Biopharma Inc?
The 52-week low of Sunshine Biopharma Inc is 0.28.
What is the market capitalization of Sunshine Biopharma Inc?
The market capitalization of Sunshine Biopharma Inc is 1.04M.
Is Sunshine Biopharma Inc (SBFM) currently rated as Buy, Hold, or Sell?
According to analysts, Sunshine Biopharma Inc (SBFM) has an overall rating of Buy, with a price target of 60.00.
What is the Earnings Per Share (EPS TTM) of Sunshine Biopharma Inc (SBFM)?
The Earnings Per Share (EPS TTM) of Sunshine Biopharma Inc (SBFM) is -14.37.